AustinPx Introduces KinetiSol™ Equipment Leasing Program
AustinPx, a leading contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement for orally administered small molecule drugs, has announced the launch of its groundbreaking KinetiLease™ program. This initiative allows pharmaceutical companies to lease AustinPx’s advanced KinetiSol™ research-scale equipment, granting them direct access to a cutting-edge amorphous dispersion manufacturing tool within their own research and development (R&D) laboratories. This announcement marks a major milestone for the company, further cementing its role as an innovator in pharmaceutical development and manufacturing.
In addition to introducing the KinetiLease™ program, AustinPx has revealed that a top 10 global biotech company has already secured the first lease agreement, demonstrating strong industry interest in this new offering. By enabling direct access to KinetiSol™ technology, AustinPx aims to accelerate the development of poorly soluble drug molecules, ultimately improving bioavailability and expanding formulation possibilities.
A Game-Changer in Drug Development
The KinetiSol™ technology is a state-of-the-art manufacturing solution specifically designed to create amorphous solid dispersions (ASDs) without the use of solvents. This capability makes it particularly advantageous for developing pharmaceutical compounds with poor solubility, including high-melting-point molecules and those exhibiting poor solvent solubility. By leveraging KinetiSol™, drug developers can enhance drug exposure, improve compressibility, achieve higher ASD loading, and facilitate favorable downstream processing. These benefits contribute to reduced pill burden for patients, a crucial factor in medication adherence and overall treatment efficacy.
Over the past three years, AustinPx has successfully employed KinetiSol™ technology in collaboration with global pharmaceutical and biotech companies. Through its fee-for-service CDMO model, the company has applied the technology to over 60 drug molecules, proving its efficacy across a diverse range of compounds. Now, with the introduction of KinetiLease™, AustinPx is expanding access to this transformative technology, allowing companies to integrate KinetiSol™ directly into their internal R&D operations.
Empowering Pharma Companies with Direct Access
Elizabeth Hickman, CEO of AustinPx, expressed enthusiasm about the new leasing initiative, emphasizing its potential to revolutionize drug development strategies across the industry.
“By offering leasing options for KinetiSol™ equipment, AustinPx is empowering pharmaceutical companies to harness this game-changing technology and rapidly explore its capabilities across their drug pipeline,” Hickman stated. “We’re excited to offer this technology to our partners, enabling them to advance their drug development efforts and accelerate innovation within their own walls.”
The KinetiLease™ program is designed to provide pharmaceutical and biotech companies with a seamless integration experience, ensuring that they can maximize the benefits of the KinetiSol™ technology without the traditional barriers associated with acquiring and implementing new manufacturing solutions. Key features of the KinetiLease™ program include:
- Comprehensive Training and Support: AustinPx provides thorough theoretical and operational training to ensure seamless onboarding and effective utilization of the KinetiSol™ equipment.
- White Glove Delivery and Installation: The company ensures a smooth transition with expert setup and calibration of the leased equipment at the client’s facility.
- Annual Preventative Maintenance: Regular maintenance ensures optimal performance, minimizing downtime and enhancing long-term reliability.
Real-World Success with KinetiSol™ Technology
AustinPx’s first KinetiSol™ lease agreement was signed with a leading global biotech company, underscoring the strong demand for innovative bioavailability-enhancing technologies. Following installation, the lease partner received comprehensive training, enabling them to quickly integrate KinetiSol™ into their workflows. Within just two weeks, the company began screening small molecule candidates and applying the technology to multiple programs in their drug development pipeline, including preclinical testing of formulation prototypes.
Chris Brough, co-inventor of KinetiSol™ Technology and Chief Technical Officer at AustinPx, highlighted the remarkable impact the technology has already demonstrated.
“We’ve seen firsthand the power of KinetiSol™ Technology to enhance the solubility of small molecule candidates,” Brough noted. “After quickly onboarding the technology, our pharma partner achieved solubility enhancement where other methods had previously failed, across multiple molecules. This success showcases KinetiSol’s exceptional capabilities in bioavailability enhancement, formulation flexibility, and speed.”
The successful integration of KinetiSol™ technology by this top-tier biotech company serves as a powerful case study, reinforcing the effectiveness of AustinPx’s innovative approach. The rapid deployment and immediate impact demonstrate how KinetiSol™ can provide a faster, simpler, and more efficient means of producing ASD formulations compared to traditional techniques.
Addressing Industry Challenges with Cutting-Edge Technology
The pharmaceutical industry faces ongoing challenges related to drug solubility and bioavailability, which are critical factors in determining a drug’s success. Many promising drug candidates fail to advance through clinical trials due to poor solubility, limiting their therapeutic potential and commercial viability. By offering a solvent-free, high-performance alternative to conventional ASD manufacturing methods, KinetiSol™ provides a breakthrough solution for these persistent challenges.
One of the key advantages of KinetiSol™ technology is its ability to efficiently process high-melting-point compounds that are otherwise difficult to formulate. Unlike spray drying or hot-melt extrusion, which may require excessive processing conditions or solvents, KinetiSol™ applies high shear forces to rapidly transform crystalline drug substances into stable amorphous dispersions. This capability expands the range of molecules that can be successfully developed into viable drug formulations.
A Strategic Move for the Future
With the launch of KinetiLease™, AustinPx is positioning itself at the forefront of pharmaceutical technology innovation. By making KinetiSol™ accessible directly within R&D labs, the company is enabling pharmaceutical developers to gain firsthand experience with the technology and accelerate their formulation optimization efforts.
The flexibility of leasing rather than purchasing equipment outright provides a cost-effective alternative for companies looking to explore new formulation technologies without committing to a significant capital investment. This approach aligns with the growing trend of pharma companies seeking adaptable, scalable solutions that enhance efficiency and innovation.
Looking ahead, AustinPx anticipates that the KinetiLease™ program will attract a broad range of pharmaceutical and biotech companies seeking to enhance their formulation capabilities. As more companies integrate KinetiSol™ into their R&D pipelines, the technology’s impact on drug development is expected to grow, ultimately leading to the creation of more effective and patient-friendly medications.
AustinPx’s introduction of the KinetiLease™ program represents a pivotal advancement in the pharmaceutical manufacturing landscape. By providing direct access to KinetiSol™ technology through an innovative leasing model, the company is breaking down barriers to adoption and enabling pharmaceutical developers to address critical solubility challenges with greater efficiency and speed.
With its proven success across numerous drug candidates, KinetiSol™ stands as a transformative tool for bioavailability enhancement. As the pharmaceutical industry continues to evolve, the availability of flexible, high-performance manufacturing solutions like KinetiSol™ will play an essential role in shaping the future of drug development. AustinPx’s strategic move with KinetiLease™ ensures that more companies can harness the power of this technology, ultimately leading to the creation of next-generation therapeutics that improve patient outcomes worldwide.
